丹龙口服液联合福多司坦口服溶液辅助治疗小儿肺炎支原体肺炎的效果观察  

Observation on the Efficacy of Danlong Oral Liquids Combined with Fudosteine Oral Liquids as Adjuvant Therapy for Mycoplasmal Pneumoniae Pneumonia

作　　者：张倩 马世清 王丹婷 ZHANG Qian;MA Shiqing;WANG Danting(Department of Pharmacy,Ankang Central Hospital,Ankang,Shaanxi 725000,China)

机构地区：[1]安康市中心医院药学部,陕西安康725000

出　　处：《临床误诊误治》2025年第9期97-103,共7页Clinical Misdiagnosis & Mistherapy

基　　金：陕西省中医药管理局2019—2020年度中医药科研项目(2019-ZZ-LC023)。

摘　　要：目的 探讨丹龙口服液联合福多司坦口服溶液辅助治疗小儿肺炎支原体肺炎(MPP)的效果。方法 选取2022年1月至2024年5月就诊的MPP患儿150例,采用随机数字表法分为对照A组、对照B组、联合组各50例。3组均给予基础治疗,对照A组给予丹龙口服液,对照B组给予福多司坦口服溶液,联合组给予丹龙口服液联合福多司坦口服溶液。比较3组临床疗效、病情康复指标、肺功能[用力肺活量(FVC)、最大呼气流量(PEF)、第一秒用力呼气容积(FEV1)]、炎性因子[白细胞介素(IL)-6、IL-17、C反应蛋白(CRP)]、免疫功能(IgM、IgG、IgA)、Toll样受体4/髓样分化因子88/核因子-κB(TLR4/MyD88/NF-κB)信号通路因子及不良反应发生率。结果 联合组总有效率[94.00%(47/50)]高于对照A组[80.00%(40/50)]、对照B组[76.00%(38/50)],差异有统计学意义(P<0.05)。联合组咳嗽、咳痰、发热、肺部湿啰音改善时间均短于对照A组、对照B组(P<0.05)。治疗后,联合组FEV1、FVC、PEF及IgA、IgM、IgG高于对照A组、对照B组,IL-6、CRP、IL-17及TLR4、MyD88、NF-κB表达水平低于对照A组、对照B组(P<0.05)。3组不良反应发生率比较差异无统计学意义(P>0.05)。结论 丹龙口服液联合福多司坦口服溶液辅助治疗MPP效果显著,可改善肺功能,促进临床病情改善,还可抑制炎症反应及TLR4/MyD88/NF-κB信号通路因子表达,增强机体免疫功能,且安全性高。Objective To investigate the effect of Danlong oral liquid combined with Fudosteine oral liquid as adjuvant therapy for mycoplasmal pneumonia pneumonia(MPP).Methods A total of 150 children with MPP who were treated in our hospital from January 2022 to May 2024 were selected and randomly divided into control group A(n=50),control group B(n=50),and combination group(n=50) by random number table method.The control group A was given Danlong oral liquid,the control group B was given Fudosteine oral liquid,and the combined group was given Danlong oral liquid combined with Fudosteine oral liquid.The clinical efficacy,disease recovery indicators,lung function [forced vital capacity(FVC),peak expiratory flow(PEF),forced expiratory volume in one second(FEV1)],inflammatory factors [interleukin(IL)-6,IL-17,C reactive protein(CRP)],immune function [immunoglobulin(Ig) M,IgG,IgA],Toll-like receptor 4/myeloid differentiation factor 88/nuclear factor-κB(TLR4/MyD88/NF-κB) signaling pathway factors,and adverse reactions were compared among the three groups.Results The total effective rate of the combination group was [94.00%(47/50)],which was higher than that of the control group A [80.00%(40/50)] and control group B [76.00%(38/50)](P<0.05).The improvement time of cough,expectoration,fever,and lung wet rale in the combination group was shorter than that in the control group A and control group B(P<0.05).After treatment,the FEV1,FVC,PEF,IgA,IgM,and IgG levels in the combination group were higher than those in the control group A and control group B,while the expression levels of IL-6,CRP,IL-17,TLR4,MyD88,and NF-κB were lower than those in the control group A and control group B(P<0.05).There was no significant difference in the incidence of adverse reactions among the three groups(P>0.05).Conclusion Danlong oral liquid combined with Fudosteine oral liquid as adjuvant therapy has significant effects in the treatment of MPP,which can improve lung function,ameliorate clinical symptoms,inhibit inflammatory reactions and the expressio

关 键 词：丹龙口服液 福多司坦口服溶液 肺炎 支原体 用力呼气量 最大呼气流量 白细胞介素-6 免疫球蛋白M TLR4/MyD88/NF-κB信号通路 儿童 

分 类 号：R563.1[医药卫生—呼吸系统]